Article Text

Download PDFPDF
Leflunomide and methotrexate combination therapy in daily clinical practice
  1. A Dendooven,
  2. L De Rycke,
  3. X Verhelst,
  4. H Mielants,
  5. E M Veys,
  6. F De Keyser
  1. Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
  1. Correspondence to:
    Dr F De Keyser
    Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium; Filip.DeKeyser{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A few years ago, the immunomodulatory molecule leflunomide was licensed as a new disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Several randomised clinical trials have established its safety and efficacy, which is comparable to that of sulfasalazine and methotrexate.1,2 Some questions remain about the performance of this agent in current therapeutic strategies.3 One particular important query about the applicability of leflunomide is its use in combination therapy with methotrexate. Although there have been some conflicting opinions, it was shown by van Riel and Weinblatt et al that such combination therapy is safe and more effective than treatment with leflunomide or methotrexate alone.4,5 …

View Full Text